ELORALINTIDE
Minimum order 2 vials or 2 pens — delivery in 2 weeks
In a 48-week phase 2 RCT (263 adults with obesity), weekly eloralintide produced dose-dependent weight loss of up to −20% at the 9 mg dose, versus −0.4% with placebo.
Illustrations of the product — not photos of a specific batch.
−20%! Yes, you read that right — up to twenty percent, at the study's highest dose, versus just −0.4% on placebo 1!
And it's not a chance observation — it's a phase 2 RCT, 263 people, 48 full weeks of follow-up. Serious science, serious number.
Dose-dependent, say the researchers — the higher the dose, the clearer the difference from placebo.
But careful, dear reader: this is a study-population average, not a promise of a personal result.
The purity of the preparation that reaches you? There we NEVER cut corners — every batch is tested.
What we don't know yet: what happens after 48 weeks. Research use — and we mean it, with all the seriousness it deserves.
−20% at 9 mg, versus −0.4% placebo. Phase 2 RCT, 263 people, 48 weeks 1. That's a clinical number, not bro-science.
Dose-dependent effect — dose up, response up. A clean dose-response curve.
Solid design: randomisation, placebo, a large sample. Not a forum anecdote.
A population average is no guarantee for you personally. A clear limit.
Everything we sell is for research. Clean batch, documented profile — no guarantee of results.
The number: up to −20% weight loss at the 9 mg dose, versus −0.4% with placebo 1.
Phase 2, randomised controlled trial (RCT), 48 weeks, 263 adults with obesity. Solid study design.
A dose-dependent effect — the higher the dose, the bigger the gap from placebo.
These are population data, study averages. They don't predict what will happen to any one person.
What we don't know: the long-term picture beyond 48 weeks, and how it behaves outside a controlled trial.
Research use, pure. The data are solid — the use remains research.
Vial: 10 mg vial · Pens: 1 × 10 mg pen.
We don't keep it in stock — it's ordered in: minimum 2 items (vials or pens) from the special-order products, with free shipping, and it arrives in about 2 weeks.
€3 shipping + €3 cash-on-delivery fee. For orders of 2 vials or pens or more, shipping and the cash-on-delivery fee are free. Delivery time depends on the courier.
Cash on delivery, paid to the courier when it arrives. For an electronic money transfer (PayPal, Revolut, Wise, crypto), email us for the details: ellinikapeptidia@gmail.com
Yes: you have a 14-day right of withdrawal from delivery, as long as the seal is intact. Return costs are yours, unless the product was faulty or wrong. Terms of Use
Want something you don't see here? Write to us — we reply.
Related products
from €44 to €176
Minimum order 2 vials or 2 pens — delivery in 2 weeks
−24.2% body weight in 48 weeks, and −82% liver fat. A triple GLP-1, GIP and glucagon agonist: it makes you eat less and burn more.
from €44 to €176
Minimum order 2 vials or 2 pens — delivery in 2 weeks
−20.9% body weight in 72 weeks, in a study of 2,539 people. A dual GLP-1 and GIP agonist: two switches instead of one — which is why the numbers are in a different league from monotherapy.
from €44 to €176
Minimum order 2 vials or 2 pens — delivery in 2 weeks
−14.9% body weight in 68 weeks — and the only one of the group proven to reduce heart attack and stroke, in 17,604 people.
from €79.20 to €140
Minimum order 2 vials or 2 pens — delivery in 2 weeks
It's not GLP-1 — it's amylin, the other satiety switch. Together with semaglutide it delivered −20.4% in 3,417 people.
from €112.80 to €128.80
Minimum order 2 vials or 2 pens — delivery in 2 weeks
GLP-1 and glucagon — no GIP. −14.0% in 48 weeks, and discontinuations due to side effects on par with placebo.
from €139.20 to €155.20
Minimum order 2 vials or 2 pens — delivery in 2 weeks
Dual GLP-1 and glucagon receptor agonist: in phase 2 (n=387) it produced up to −14.9% body weight at 46 weeks.
€0
Fill in and send. A person replies, not an automated message.